Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Key takeaways from the top ASH abstracts in the myelofbrosis space.
Advertisement
A roundtale discussion starts with a conversation about the myelofibrosis treatment landscape.
Discussing current clinical trials iand unmet needs in myelofibrosis.
The PROMise trial aims to examine the safety and preliminary efficacy of OPN-2853 with ruxolitinib for MF treatment.
Odyssey is an ongoing, open-label, phase 2 study that will assess the benefit of adding luspatercept to momelotinib.
At ASH 2024, updated results of the RESTORE trial were presented.
These real-world findings highlight momelotinib as an effective and practical treatment for managing MF in everyday practice
BOREAS is the first global phase 3 study to demonstrate clinical efficacy of a single-agent treatment for r/r myelofibrosis.
John Masarenhas discussed the development of the human telomerase inhibitor imetelstat for the treatment of myelofibrosis.
Improvements in the frequency of transfusions and of anemia symptoms are interventional priorities for myelofibrosis.
A phase 2 trial showed selinexor was well tolerated, and further studies are investigating its efficacy in other MF settings.
Ruxolitinib is the standard of care for patients with MF; however, it does not address the significant anemia burden.
A retrospective, real-world analysis shows momelotinib reduces anemia in patients with myelofibrosis.
HOPE-PMF will recruit 150 participants with prefibrotic PMF or PMF at low or intermediate-1 risk.
Study findings indicate that allo-HSCT may offer a potentially curative treatment for high-risk BP-MF patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.